HIGHLIGHTS
- who: Aditya Bardia from the General Hospital, Boston, MA, Memorial Sloan Kettering Cancer Center, New York, NY, USA. , University have published the research: AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer, in the Journal: NATURE COMMUNICATIONS NATURE COMMUNICATIONS of 26/03/2020
- what: The authors report the final results from Arm 1 of the Phase 1/2 study (AMEERA-1) among postmenopausal women with ER+/HER2- advanced breast cancer, which evaluates the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of amcenestrant administered as monotherapy . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.